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ABSTRACT
Alcohol Consumption in a Preclinical Model of Schizophrenia
by
Liza J. Hernandez
Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the global
population. Schizophrenia is highly comorbid with other psychiatric disorders such as Alcohol
Use Disorder (AUD) with a prevalence rate of 27% - 65%, which is significantly higher than
AUD exhibited by the general population (6%). Research indicates that a higher rate of AUD in
individuals suffering from schizophrenia may be related to the common neuronal pathways that
underlie the expression of both disorders. The present study will determine whether the neonatal
quinpirole (NQ) rodent model of schizophrenia will approximate the human condition and
exhibit increased EtOH consumption. Rats will be treated neonatally with quinpirole or saline.
Following the treatment period, rats will be tested for EtOH consumption using a 24-hour twobottle free-access paradigm. The proposed research will test the hypothesis that rats neonatally
treated with quinpirole will consume significantly greater amounts of EtOH than their saline
counterparts.
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CHAPTER 1
INTRODUCTION
Schizophrenia is a debilitating psychiatric disorder that affects approximately 1% of the
global population (McGrath, Saha, Chant, & Welham, 2008; Khokhar, Dwiel, Henricks,
Doucette, & Green, 2018). Schizophrenia carries the fourth highest psychiatric disease burden
worldwide due to early age of onset, lifelong impairments (social, occupational, & cognitive),
and premature mortality (Miettunen, Immonen, McGrath, Isohanni, & Jääskeläinen, 2018;
Whiteford, Ferrari, Degenhardt, Feigin, & Vos, 2015). For instance, a recent meta-analysis
indicated that individuals with schizophrenia die an average of 13-15 years earlier than nonschizophrenic individuals due to factors that include: somatic disorders (e.g. cardiovascular
disease & diabetes), side effects from second-generation antipsychotics (e.g. olanzapine), poor
lifestyle (e.g. sedentary behavior & poor dietary habits), reduction of health-seeking behavior,
and increased frequency of illicit and licit drug use (e.g. tobacco, marijuana & alcohol (EtOH);
Hjorthøj, Stürup, McGrath, & Nordentoft, 2017). However, since schizophrenia is a spectrum
disorder without a single diagnosis, a wide range of severities as well as a complex etiology (e.g.
genetic and environmental factors), there is limited understanding of this disorder and further
research is needed (Horváth & Mirnics, 2015).
Schizophrenia is characterized by multiple symptom clusters that include positive,
negative, and cognitive symptoms. Positive symptoms include delusions (believing in something
that cannot be true), hallucinations (false sensory experiences), disorganized thought or speech,
and disorganized or abnormal motor behavior (APA, 2014; NIMH, 2016). Negative symptoms
include blunted affect, avolition (difficulty in initiating or sustaining activities), alogia (reduction
in verbal communication), anhedonia (decreased enjoyment in pleasurable activities), and
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asociality (lack of interest in socializing), with the DSM-5 classifying blunted affect and
avolition as the most prevalent negative symptoms (APA, 2014). Cognitive symptoms are
manifested as deficits in attention, memory (e.g. working memory and declarative memory),
executive functioning (e.g. regulation of thoughts, behaviors, and emotions to attain a goal), and
recognition of having a disorder (i.e. anosognosia). People with schizophrenia have reported
difficulties in completing educational and vocational tasks due to decreased executive
functioning (Nestler, Hyman, Holtzman, & Malenka, 2015).
Overall, the severity of positive and negative symptoms combined with poor social
functioning is directly correlated with treatment outcome success for individuals suffering from
schizophrenia (Di Michele & Bolino, 2004). Numerous treatment methods are used to manage
symptoms, including psychosocial (e.g. psychotherapy, social skills training, and vocational
rehabilitation) and pharmacological interventions (e.g. antipsychotics; Mayo Clinic, 2018).
However, numerous factors such as delusion of paranoia, anosognosia, and/ or substance use
disorders contribute to a failure to maintain an adequate treatment regimen in 50% of patients
(Haddad, Brain, & Scott, 2014). This is of great concern as noncompliance is associated with
several negative outcomes including hospitalization, reoccurring positive symptoms, enhanced
negative symptoms, decreased quality of life, substance abuse, and self-harm (Haddad et al.,
2014). Additionally, there is evidence that adolescent substance abuse (e.g. EtOH and cannabis
use) is positively correlated with the onset of psychotic symptoms in people later diagnosed with
schizophrenia, suggesting an important relationship between drug use and disorder progression
(Hambrecht & Häfner, 1996; Semple, McIntosh, & Lawrie, 2005; van Nimwegen, de Haan, van
Beveren, van den Brink, & Linszen, 2005).
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Adolescent Period of Development
The adolescent period of development is indicative of the developmental stage that
segregates childhood from adulthood. During this period of development, an abundance of
alterations are occurring in the brain. Behaviorally, there is an increased tendency to explore and
seek out euphoric experiences (such as sex and drug use; Walker et al., 2017). The promotion of
exploration is most likely due to neuronal synaptic pruning and an underdeveloped reward circuit
(Nimwegen, Haan, Beveren, Brink & Linszen, 2005). During the reorganization of this circuitry
adolescents not only have an elevated risk and enhanced reward-sensitivity towards using drugs
but also display a reduction in sensitivity toward the aversive effects of drugs (DoremusFitzwater & Spear, 2016).

Schizophrenia Comorbid with Alcohol Use Disorder
Research indicates that individuals diagnosed with schizophrenia have a significantly
higher risk of developing an alcohol-use disorder (AUD; APA, 2014; Green, Drake, Brunette, &
Noordsy, 2007; Khokhar et al., 2018) however, the literature differs drastically on the prevalence
of comorbid schizophrenia and AUD, ranging from 27% (Thoma & Daum, 2013) to 65%
(Volkow, 2009). Regardless of the specific prevalence, it is clear that individuals suffering from
schizophrenia are at a much greater risk to develop a comorbid AUD than the general population
(6.2%; NIAAA, 2018). Schizophrenia comorbid with AUD is typically exhibited by males that
experienced an earlier onset of the disorder and leads to greater severity of extrapyramidal,
positive symptoms (Thoma & Daum, 2013). Moreover, comorbid expression of schizophrenia
and AUD is associated with an increased likelihood of several negative outcomes including;
lower quality of life, increased treatment non-compliance rates, increased violent behavior, risk
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of suicide, homelessness, and hospitalization (Green et al., 2007; Thoma & Daum, 2013;
Khokhar et al., 2018).
There are two predominant hypotheses as to the high prevalence of comorbid
schizophrenia and AUD. An initial theory, the self-medicating hypothesis (SMH), suggests that
people abuse drugs deliberately based on the psychopharmacological effects that provide relief
from the symptoms associated with schizophrenia (Chambers, Krystal, & Self, 2001; Goswami,
Mattoo, Basu, & Singh, 2004; Khantzian, 1985). For instance, people with schizophrenia have
reported that EtOH consumption alleviates positive and negative symptoms including,
hallucinations, delusions, anhedonia, asociality, and anxiety (Addington & Duchak, 1997;
Chambers, Krystal, & Self, 2001; Thoma & Daum, 2013). A second theory, the primary
addiction hypothesis, postulates that individuals suffering from schizophrenia have a heightened
risk of developing an AUD as both disorders affect common brain pathways (Volkow, 2009).
Specifically, the atypical neuropathology of schizophrenia also produces alterations in the
regulation of positive reinforcement, incentive salience, behavioral inhibition, and addictive
behavior due to the dysregulation of the mesocorticolimbic circuitry (Chambers, Krystal, & Self,
2001). It is important to delineate the nature of the disruptions in the neuropathology pertaining
to schizophrenia to further understand the enhanced comorbidity of SUDs in this population as
well as to research novel treatment methods.
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CHAPTER 2
LITERATURE REVIEW
Nestler and colleagues (2015) indicated that schizophrenia and AUD are independent
disorders derived from abnormalities primarily in the mesocorticolimbic circuitry. The
mesocorticolimbic dopamine (DA) pathway has been thoroughly established in both humans and
nonhuman animals, to be involved in the manifestation of several symptoms associated with
schizophrenia, as well as motivation and reward, (for review see Brisch et al., 2004; see also
Fallon & Moore, 1978; Oleson & Roberts, 2018; Wise, 2004) and has been further divided into
the mesolimbic and the mesocortical pathways (Chinta & Andersen, 2004). Both pathways are
comprised predominantly of DA neurons in the ventral tegmental area (VTA) projecting to
various regions of the brain including the nucleus accumbens (Acb), olfactory tubercles,
amygdala, hippocampus, septum, prefrontal cortex (PFC), cingulate cortex, and perirhinal cortex
(Adinoff, 2004; Chinta & Andersen,2004; Gardner, 2011; Olds, & Milner, 1954; Wise, &
Bozarth, 1984). Research has found that DA neuronal activation in the mesolimbic pathway is
primarily associated with pleasurable stimuli (e.g. food, sex, social interactions, or drugs; for
review see Ikemoto, 2007). DA signaling within the mesocortical pathway has been linked to
executive functions such as working memory, goal-directed behaviors, and attention (Siddiqui,
Chatterjee, Kumar, Siddiqui, & Goyal, 2008). Thus, disruption of the mesocorticolimbic circuit
has been implicated in numerous disorders, including schizophrenia and AUD (Nestler et al.,
2015).
Mesocorticolimbic Circuitry and Schizophrenia
Malfunction within the mesolimbic pathway contributes to the positive symptoms of
schizophrenia (e.g. hallucinations and delusions; Nestler et al., 2015). Evidence suggesting the
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involvement of this pathway in schizophrenia was first reported when DA D2 receptor (D2-R)
antagonist administration resulted in a significant reduction of psychoses in patients diagnosed
with schizophrenia (Chambers et al., 2001; Crow, Deakin, & Longden, 1977). Additionally,
psychostimulants have been shown to induce psychotic-like effects in human and animal subjects
causing DA dysregulation (Chambers et al., 2001; Connell, 1957; Laviolette, 2007; Lodge &
Grace, 2007; McCollum & Roberts, 2015). Using functional magnetic resonance imaging
(fMRI), patients with schizophrenia were asked to perform a memory retrieval task, and
individuals who did not display hippocampal activation during the task also exhibited
psychosocial impairments (Weiss et al., 2003). Increased amygdala activation is prevalent in
schizophrenia, causing abnormal classifications of aversive or threating stimuli (Kumakura et al.,
2007). Similarly, an increase of amygdala activation in schizophrenia patients induces a
heightened bias towards aversive processing by over-emphasizing emotions associated with a
specific sensory stimulus leading to delusions (Laviolette, 2007; Pankow et al., 2013).
The mesocortical pathway has been implicated in both the negative and cognitive
symptoms of schizophrenia. Aberrations in neural processing of the PFC contribute to decreased
motivation, drive, and hygiene, as well as asociality and impairment of intuition and judgment
(Knable & Weinberger, 1997). Evidence suggests that negative and cognitive symptoms are a
result of hypoactivity of DA released from the VTA to the PFC, as well as dysfunction of the DA
D1 receptor, which primarily mediates DA transmission (Chambers et al., 2001; Knable &
Weinberger, 1997; McCutcheon, Abi-Dargham, & Howes, 2019; Slistein et al., 2015; Thoma &
Daum, 2013). Disruption in DA transmission observed in schizophrenia patients has been
associated with abnormalities in “top-down processing” of the PFC ultimately affecting
cognition (Lesh, Niendam, Minzenberg, & Carter, 2011). Specifically, researchers conducted
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fMRI studies to indicate that the dorsolateral PFC (DLPFC), anterior cingulate cortex, and the
mediodorsal thalamus are DA deficient possibly leading to cognitive deficits in schizophrenia
patients (Minzenberg, Laird, Thelen, Carter, & Glahn, 2009).
Mesocorticolimbic Circuitry and AUD
The mesolimbic pathway is believed to mediate the reinforcing effects of EtOH, as well
as play a key role in EtOH craving and relapse (For review see: Gilpin & Koob, 2008; see also
Eisenhardt, Leixner, Luján, Spanagel, & Bilbao, 2015; Imperato & Di Chiara, 1986). EtOH has
been shown to stimulate DA neurons that project from the VTA to the Acb and the amygdala (Di
Chiara & Imperato, 1988; Engel & Jerlhag, 2014; Fadda, Mosca, Colombo, & Gessa, 1989;
Yoshimoto et al., 2000). For instance, EtOH enhances the firing rate of VTA DA neurons
stimulating DA release in the shell of the Acb (AcbSh; for review see Deehan, Brodie, & Rodd,
2013; see also Bassareo et al., 2003; Deehan et al., 2016; Engel & Jerlhag, 2014). EtOH
consumption has also been found to enhance associative learning by stimulating DA
transmission to the amygdala, thereby increasing the emotional salience of EtOH (Di Chiara et
al., 1999). Furthermore, EtOH interacts with other neurotransmitters causing an indirect increase
of extracellular DA (Engel & Jerlhag, 2014). Critically, co-infusion of compounds that inhibit
DA signaling (e.g., DA D2-receptor agonist, quinpirole) in this pathway produce reductions in
the self-administration of EtOH into the posterior VTA suggesting that the reinforcing properties
of EtOH in the mesolimbic DA pathway are dependent on DA neuronal activation (Rodd et al.,
2004, 2005).
The mesocortical pathway has also been implicated in drug-seeking behaviors and drug
dependence and has been shown to control compulsory behaviors directed toward obtaining
EtOH, the suppression of thoughts associated with EtOH, and “hyper-responsiveness” to EtOH-
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associated stimuli (Adinoff, 2004; Feltenstein & See, 2013). Acute EtOH administration results
in a decrease in PFC functioning that contributes to deficits in planning and spatial recognition
tasks (Abernathy, Chandler, & Woodward, 2010; Weissenborn & Duka, 2003). Data indicate
that the rewarding effects of acute EtOH intake are, in part, mediated by DA release within the
PFC (Lammel et al., 2008; Trantham-Davidson & Chandler, 2015). However, chronic EtOH
intake is associated with a decrease in DA signaling from the VTA to the PFC producing
anhedonia and blunted reward processing during withdrawal (Trantham-Davidson & Chandler,
2015). Researchers have found that AUD causes decreased grey matter in the DLPFC which
results in a decrease in neuronal processing (Jernigan et al., 1991; Yang et al., 2016).
Unfortunately, the research is lacking as to the biological underpinning of decreased DA
transmission during chronic EtOH exposure (Trantham-Davidson & Chandler, 2015).
Modeling in Preclinical Research
Gestational Methylazoxymethanol Acetate Model (MAM)
The gestational MAM model has been extensively used as a developmental model of
schizophrenia (Ratajczak, Woźniak, & Nowakowska, 2013). The model was developed in
response to research suggesting that schizophrenia is attributed to significant gestational distress
(e.g. influenza or malnutrition) to the fetus, during the second trimester of pregnancy (Jones,
Watson, Fone, 2011). MAM is a neurotoxin that inhibits DNA synthesis, causing apoptosis in
cells that are actively replicating DNA (Talamini, Koch, Ter Host, & Korf, 1998). Interestingly,
MAM does not affect glial cells or peripheral organs making it a practical method for modeling
schizophrenia (Jones et al., 2011; Ratajczak et al., 2013). Pregnant female rats are treated with
MAM on gestational day (GD) 17 when the fetus has completed brain cortex proliferation, but
subcortical regions are still undergoing development (Jones et al., 2011). The treatment causes
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reductions in the size of several regions of the neocortical and limbic systems (medial prefrontal
cortex, entorhinal cortex, hippocampus, and occipital cortex), which is consistent with the
clinical histopathology observed in schizophrenia (Talamini et al., 1998; Lodge & Grace, 2009;
Jones et al., 2011; Ratajczak et al., 2013). However, studies have not been able to exhibit an
alleviation of symptoms caused by MAM when rodents are administered typical or atypical
antipsychotics (For review see: Jones, 2011). There is a limited amount of research conducted on
female rats exposed to MAM during GD 17 (Perez, Donegan, & Lodge, 2019), which is
concerning given that schizophrenia affects males and females equally (Li, Ma, G. Wang, Yang,
& C. Wang, 2016). Finally, MAM is a known carcinogen and exposure is potentially hazardous
to laboratory personnel, thus extreme caution must be utilized when handling the compound
(Lodge, 2013).
Neonatal Ventral Hippocampal Lesion Model (NVHL)
The NVHL model was developed to approximate abnormalities in the ventral
hippocampus (VH) that have been reported in people suffering from schizophrenia (Lipska,
Jaskiw, Chrapusta, Karoum, & Weinberger, 1992). On postnatal day (PND) 7 rats are bilaterally
infused with ibotenic acid in the VH causing irreversible ablation and disruption of the
hippocampal formation (For review see: Lipska & Weinberger, 2002; see also Lipska, Jaskiw, &
Weinberger, 1993). The VH lesions progressively produce DA-related behavioral and molecular
changes during late adolescence into early adulthood that approximate the clinical population
with schizophrenia such as increases in mesolimbic DA activity and inhibition of cortical DA
activity (Khokhar & Todd, 2018; Lipska & Weinberger, 1995; Tseng, Chambers, & Lipska,
2009). It has also been noted that mortality rates for the NVHL surgery are approximately 15%
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(Richtand et al. 2005) and 30-33% of rodents show unilateral damage leading to failure to reach
the histopathological criteria of schizophrenia (Jones et al., 2011).
Neonatal Quinpirole Model of Schizophrenia
Quinpirole is a DA D2/D3-receptor agonist that creates a lifelong enhanced sensitization,
but not overall quantity, of D2 receptors (D2-R) following chronic intraperitoneal (i.p.; 1mg/kg)
injections during the neonatal period (PND 1-21; Kostrezewa, 1993; Peterson et al., 2017;
Rodrigo et al., 2011). The enhanced sensitization of D2 receptors is behaviorally manifested as
stereotypy (i.e. clockwise lateral movement), and abnormalities in locomotion, learning, and
memory (Kostrzewa, Nowak, Brus, & Brown, 2016; Rodrigo et al., 2011), which is also
observed in the human population with schizophrenia (For review see: Weidenauer et al., 2017).
The unchanged quantity of D2-R is important because this aspect of the model is also consistent
with findings in the clinical population (Kostrezewa et al., 2016). DA receptor sensitivity can be
behaviorally measured in increases of locomotion, yawning, stereotypies, and vertical jumping,
deficits can also be observed in cognitive tasks (Kostrezewa, 1993).
The neonatal quinpirole (NQ) model exhibits face validity concerning atypical behaviors. For
example, D2 supersensitization in rodents creates deficits in prepulse inhibition (PPI;
sensorimotor gating; Kostrezewa et al., 2016; Maple, Smith, Perna, & Brown, 2015) which is
indicative of deficits in information processing that are associated with schizophrenia (Brisch et
al., 2014; Maple et al., 2015). In humans diagnosed with schizophrenia, PPI deficits are directly
correlated with the severity of positive symptoms which are markedly reduced by antipsychotic
drugs (Meincke et al., 2004). Similarly, PPI deficits in NQ rats can be attenuated by the
administration of an antipsychotic (Maple et al., 2015).
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Construct validity is demonstrated when a preclinical model and a human disorder share
a common biological factor, such as a genetic mutation (Kostrezewa et al., 2016). In the NQ
model, brain-derived neurotrophic factor (BDNF) is significantly reduced, similar to humans
with schizophrenia (Maple et al., 2015). BDNF is imperative for CNS neurogenesis by
increasing cell survival (Durany et al., 2001) and disruption in BDNF levels is believed to
contribute to the neuropathology of schizophrenia in the affected brain regions (Favalli, Li,
Belmonte-de-Abreu, Wong, & Daskalakis, 2012). The NQ model displays deficits in
hippocampal BDNF expression resulting in cognitive aberrations (Brown, Gass, & Kostrzewa,
2002; Thacker et al., 2006). Coincidentally, Durany and colleagues (2001) observed
hippocampal BDNF deficits in postmortem patients diagnosed with schizophrenia. In the NQ
model, microdialysis studies have indicated significant increases in DA outflow of the Acb
compared to control rats, which is similar to the observed increased accumbal DA levels in the
clinical population (Cope et al., 2010).
Predictive validity is established when a preclinical model successfully responds to
human treatment (Belzung & Lemoine, 2011). The common treatment for schizophrenia is the
administration of antipsychotics, such as haloperidol (typical antipsychotic) or clozapine and
olanzapine (atypical antipsychotic; Patel, Cherian, Gohil, & Atkinson, 2014). The function of
typical antipsychotics is to block DA from binding to D2-R resulting in reductions of DA
transmission to the Acb (Seeman, 2002). The administration of antipsychotics in NQ rats creates
a marked reduction of cognitive symptoms demonstrated in Morris Water Maze (MWM)
performance (Thacker et al., 2006). The MWM is a hippocampal spatial learning task for
rodents, in which there is a platform submerged in water and rodents must use spatial navigation
and reference memory to find the platform for a set number of trials (Morris, 1984; Vorhees &
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Williams, 2006). When NQ rats were administered olanzapine in adulthood, they exhibit an
alleviation of cognitive deficits demonstrated by an increased performance on the MWM
(Thacker et al., 2006). Additionally, the conditioned place preference (CPP) task can
demonstrate the associative properties formed nicotine and the context in which the rats received
the drug (Brown et al., 2018; Perna, Henderson, Bruner, & Brown, 2011). The CPP paradigm
implements the principles of classical conditioning to assess the associative properties of a
stimulus by measuring the amount of time spent in a particular area that was paired with the
stimulus (Tzschentke, 2007). Interestingly, the administration of haloperidol blocked the
associative effects of nicotine in both the NQ rats and the saline rats, but clozapine only blocked
associative effects of nicotine in NQ treated animals (Brown et al., 2018a).
Animal Models of Schizophrenia and AUD
Several studies investigating the comorbidity of SUDs using animal models of
schizophrenia have provided mixed findings (For review see: Ng, McGirr, Wong, & Roder,
2013; see also Amitai & Markou, 2009; Rezvani, Kholdebarin, Dawson, & Lavin, 2008). Only
two models have been studied relative to SUDs. Studies utilizing the NVHL model of
schizophrenia have found that VH lesioned rats will self-administer multiple substances (e.g.
cocaine, methamphetamine, nicotine, and EtOH) and become sensitized to the substances more
quickly than control rats in a similar fashion to the human population exhibiting comorbid
schizophrenia and SUD (Berg, Sentir, Bell, Engleman, & Chambers, 2015; Brady, McCallum,
Glick, & O’Donnell, 2008; Chambers & Self, 2002; Khokar & Todd, 2018). Evidence also exists
that adolescent EtOH consumption produces an increase in adult EtOH drinking in NVHL
animals (Jeanblanc et al. 2014). This correlates with human schizophrenia research indicating
that prodromal EtOH exposure in adolescence is associated with AUD in adulthood (Jeanblanc et
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al. 2014; Khokar & Todd, 2018). To date, however, the majority of research on drug use in the
NQ model has focused on the addictive properties of stimulants (e.g. nicotine and amphetamines;
Cope et al., 2010; Peterson et al., 2017). Prior to the current study, there has not been any work
to analyze whether EtOH consumption would be affected in the NQ model of schizophrenia.
Current Study
The prevalence of AUD in people diagnosed with schizophrenia is significantly higher
than the general population, with rates reaching upwards of 65% (Volkow, 2009). The neuronal
mechanisms associated with these disorders are not well understood, therefore further research is
necessary. This project seeks to analyze ethanol drinking behavior in a preclinical model of
schizophrenia as a preliminary step to potentially understand the underlying aberrations in
neurotransmitter signaling that manifest in schizophrenia and AUD. The purpose of assessing
EtOH consumption in this model is to produce supplementary information on the common
neuronal pathways that intersect schizophrenia and AUD. Based on the literature review above
the hypotheses of the proposal are as follows:
•

H1: The neonatal quinpirole model will prove to be predictively valid in assessing

EtOH consumption in a preclinical model of schizophrenia comorbid AUD.
•

H2a: Rats neonatally treated with quinpirole during PND 1-21 will consume

significantly more EtOH than their saline counterparts during both exposure periods
(PND 28-42, PND 75-120).
•

H2b: Rats neonatally treated with quinpirole during PND 1-21 will significantly

consume more EtOH than their saline counterparts during the first exposure period
(PND 28-42).
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•

H2c: Rats neonatally treated with quinpirole during PND 1-21 will significantly

consume more EtOH than their saline counterparts during the second exposure
period (PND 75-120).
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CHAPTER 3
METHODS
Subjects
Adolescent NQ female Sprague Dawley rats were 22 days old when obtained from
Brown Laboratory (Mountain Home, TN) and group housed until PND 28. Male and female
adult Sprague Dawley breeders were ordered (Envigo Inc., Indianapolis, IN) and housed together
until females are approximately at gestational day (GD) 17 at which point pregnant dams were
singly housed. Rat pups were born at approximately GD 22 which represented post-natal day
(PND) 0. The rat pups resided with the female dam until PND 21 when they were weaned, and
group housed until PND 28. Animals were derived from four litters and group assignments were
based on neonatal treatment and EtOH concentration exposure in adolescence and adulthood
(Table 1). Animals were housed in a reverse 12-h light/dark cycle. Food and water were
available ad libitum throughout the experiment. All procedures were approved by East
Tennessee State University Animal Care and Use Committee prior to initiation.
Table 1.
Group Assignment Table

Quinpirole (NQ 10-20)
n = 10

Quinpirole (NQ 10-10)
n = 10

Saline
n = 10

Adolescent Ethanol
Concentration

10% (v/v)

10% (v/v)

10% (v/v)

Adulthood Ethanol
Concentration

20% (v/v)

10% (v/v)

20% (v/v)

22

Drugs and Solution
Quinpirole hydrochloride (Sigma Aldrich, St. Louis, MO) was diluted with 0.9% (w/v)
isotonic saline (Ricca Chemical Company, Arlington, TX) to form a 1 mg/kg concentration. 190
proof EtOH (Pharmco by Greenfield Global, Inc., Shelbyville, KY) was diluted with deionized
water to 10% (v/v) and 20% (v/v) EtOH concentrations.
Procedure
Rats were given single daily intraperitoneal (i.p.) injections of either quinpirole HCL (1
mg/kg) or 0.9% saline (1 mg/kg) based on body weight from PND 1-21. On PND 21 rats were
weaned from the dam and group-housed (3-4 to a cage). On PND 28, all rats were singly housed
in order to assess adolescent EtOH consumption.
Two-bottle Choice Task with Two Exposure Periods
Animals were tested for EtOH consumption using a 24-hour 2 bottle free-access
paradigm. The timing of EtOH access approximated previous research examining EtOH
consumption in animal models of schizophrenia (Jeanblanc et al., 2014). Rats were exposed to
EtOH during two developmental periods. The first exposure occurred during adolescence (PND
28-42) and the second occurred during adulthood (PND 75-120). During both exposure periods,
rats were provided with two Ancare (Bellmore, NY) screw top bottles on their home cage. In the
first exposure period (PND 28-42) the bottles contained either 10% (v/v) EtOH or tap water. On
PND 42 the EtOH bottles were removed and the rats had access only to tap water. The second
exposure period (PND 75-120) the bottles contained either 10% EtOH (NQ 10-10), 20% EtOH
(v/v; NQ 10-20 & Saline) or tap water. On PND 90 the EtOH bottles were removed and the rats
had access to tap water only. During the two exposure periods, food and fluid intake and body
weights were recorded daily.
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Statistical Analysis
Daily readings of body weight and the consumption of EtOH, water, and food were
recorded into a spreadsheet using Microsoft Excel (2019). Daily means and standard errors of
consumption (EtOH, water, and food) were calculated for each group. To properly assess EtOH
intake, ml of EtOH consumed was converted to grams of EtOH consumed by animal body
weight in order to obtain the amount of intake relative to the animal's body weight. Daily intake
graphs were created using GraphPad Prism 6 (2017). EtOH intake data was organized into JASP
0.9.2 (2019) to investigate the effect of EtOH consumption during two Exposure Periods
(Adolescence vs. Adulthood) by Neonatal Treatment (NQ 10-20, NQ 10-10, & Saline) and a
repeated-measures ANOVA with Neonatal Treatment as the between-subjects factor and
Exposure Period as a within-subject factor was fitted to the data. Since the exposure period was a
repeated measure of EtOH consumption (g/kg). The alpha criterion was set at p < 0.05 to further
investigate significant interactions. Outliers were defined as data anomalies that were two
standard deviations above or below the mean. When outliers were identified the datapoint was
reverted to the mean. In order to determine the significance of body weights, food and water
consumption on individual days of exposure, between the three groups, a one-way ANOVA was
fitted to the data using aov function (stats package) and PostHocTest (DescTools; Signorell et al.,
2019) in R 3.6.0 (2019). Since there were 28 days of exposure, p-values acquired from the oneway ANOVAs were adjusted using the R package stats (2019) with Benjamini – Hochberg
corrections in order to decrease the false-discovery rate (Benjamini & Hochberg, 1995).
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CHAPTER 4
RESULTS
The descriptive measurements for EtOH consumption are presented in Table 1. An
ethanol bottle leaked causing an animal in the NQ 10-20 group to display larger than possible
ethanol consumption, thus this data point was reverted to the group mean (Table 2). A two-way
ANOVA (Days of EtOH Exposure by Neonatal Treatment Group) with repeated measures was
fit to the data. Mauchly's test indicated that the data violated the sphericity assumption, therefore
sphericity corrections using Greenhouse – Geisser were implemented and are shown in Table 3.
The repeated measures ANOVA demonstrated an increase in EtOH consumption, as it revealed a
significant between-subjects effect of Neonatal Treatment (F(2,27) = 4.259, p = 0.025, η2 = 0.240),
a significant within-subjects effect of Days of EtOH Exposure (F(8.926, 241.001) = 7.717, p < 0.001,
η2 = 0.191; Figure 1), and an interaction effect of Neonatal Treatment by Days of EtOH
Exposure (F(17.852, 241.001) = 2.813, p < 0.001, η2 = 0.139). A Benjamini-Hochberg post hoc test
revealed that the NQ 10-10 and Saline groups differed significantly at p = 0.020. Pairwise
comparisons were fit to the data to assess group differences of EtOH consumption during
individual days (Figure 2) indicating that NQ 10-10 group consumed more EtOH than NQ 10-20
and Saline groups on PND 83; 85-87; 89 (p’s < 0.05, Fig. 2) and NQ 10-10 group had a greater
intake of EtOH than the Saline group on PND 84 (p’s < 0.05, Fig. 2). NQ 10-20 group consumed
more EtOH than NQ 10-10 group on PND 77-78 (p’s < 0.05, Fig 2).
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Adolescence

Adulthood

Exposure Period

Figure 1. Overall mean (+ SEM) EtOH consumption between Exposure Period. * represents
Adulthood mean EtOH consumption is significantly greater than Adolescent mean
consumption, p < 0.05.
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10-20
10-10
@

Figure 2. Treatment Group mean (+ SEM) of EtOH consumption during each day of EtOH
exposure. Figure A represents the Adolescent Exposure Period while Figure B denotes the
Adulthood period. There was a significant interaction effect between the NQ #2 & Saline,
denoted by * in the legend. @ represent NQ 10-20 being significantly higher than NQ 10-10
& Saline. # represent NQ 10-20 being significantly higher than NQ 10-10. * represent NQ
10-10 being significantly higher than NQ 10-20 and Saline and $ represent NQ 10-10 being
significantly higher than Saline. Significance determined through pairwise comparisons
using Benjamini-Hochberg corrections (p’s < 0.05).

Body Weight and Food and Water Consumption
Bodyweight and food and water consumption (grams) during adolescence and adulthood
were examined between Neonatal Treatment Groups (NQ 10-20 vs. NQ 10-10 vs. Saline). Means
and standard deviations of Exposure Period between Treatment group are presented in Table 3.
Body Weights
A repeated-measures ANOVA (Days of EtOH Exposure by Neonatal Treatment Group)
was fit to the data. Mauchly's test indicated that the data violated the sphericity assumption,
therefore sphericity corrections using Greenhouse – Geisser were implemented. The repeated
measures ANOVA demonstrated an increase in body weight, as it revealed a significant
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between-subjects effect of Neonatal Treatment (F(2,27) = 7.261, p = 0.003, η2 = 0.350), a
significant within-subjects effect of Days of EtOH Exposure (F(1.448, 39.103) = 2348.90, p < 0.001,
η2 = 0.980), and an interaction effect of Neonatal Treatment by Days of EtOH Exposure (F(2.897,
39.103)

= 10.01, p < 0.001, η2 = 0.008). A post hoc Benjamini-Hochberg test revealed that the NQ

10-20 and Saline groups differed significantly at p = 0.003.
Pairwise comparisons using one-way ANOVAs were fit to each day and the p values
were adjusted using Benjamini-Hochberg corrections. The comparisons indicated that the NQ
10-20 group weighed significantly more than the Saline group during the Adolescent Exposure
Period on PND 37 - 41 (p’s < 0.043, Fig. 3), with mean weight differences of 21.072 grams.
During Adulthood and PND, 42 NQ 10-20 and NQ 10-10 groups weighed significantly more
than Saline groups on PND 76 - 89 (p’s < 0.001, Fig. 3), with mean weight differences of 41.816
grams.
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*
10-20
10-10

Figure 3. Treatment Group mean (+ SEM) body weight during each day of EtOH exposure.
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period.
There was a significant interaction effect between the NQ 10-20 & Saline, denoted by * in the
legend. ^ represent NQ 10-20 being significantly higher than Saline. * represents NQ 10-20 &
NQ #2 being significantly higher than Saline. Significance determined through pairwise
comparisons using Benjamini-Hochberg corrections (p’s < 0.05).

Food Intake
The analysis of food consumption commenced on PND 34 rather than PND 28
because the pups were recently weaned and separated from their siblings. To view whether food
intake differed, a two-way ANOVA (Days of EtOH Exposure by Neonatal Treatment Group)
with repeated measures was fit to the data. Mauchly's test indicated that the data violated the
sphericity assumption, therefore sphericity corrections using Greenhouse – Geisser were
implemented. The repeated measures ANOVA demonstrated a difference in food consumption,
as it revealed a significant between-subjects effect of Neonatal Treatment (F(2,27) = 8.159, p =
0.002, η2 = 0.377), a significant within-subjects effect of Days of EtOH Exposure (F(7.497, 202.427)
= 6.154, p < 0.001, η2 = 0.145), and an interaction effect of Neonatal Treatment by Days of
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EtOH Exposure (F(14.995, 202.427) = 4.630, p < 0.001, η2 = 0.218). A post hoc Tukey’s test revealed
that the NQ 10-20 and NQ 10-10 groups differed significantly at p = 0.006 and that NQ 10-20
and Saline groups differed significantly at p = 0.004.
Pairwise comparisons were fit to the data to assess group differences of food
consumption during individual days (Figure 4) indicating that the NQ 10-20 group consumed
significantly more food than the NQ 10-10 and the Saline group during the Adolescent Exposure
Period on PND 42 (p’s < 0.05, Fig. 4). During Adulthood the NQ 10-20 group consumed
significantly more food than the NQ 10-10 and Saline groups on PND 77, 80 and 88 (p’s <
0.028, Fig. 4). NQ 10-20 and NQ 10-10 groups consumed significantly more than the Saline
group on PND 83 (p = 0.030, Fig. 4). NQ 10-20 and Saline groups consumed significantly more
than the NQ 10-10 group on PND 86 (p < 0.001, Fig. 4).
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10-20
10-10

PND
Figure 4. Treatment Group mean (+ SEM) food intake during each day of EtOH exposure.
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period.
There was a main effect of interaction in that NQ 10-20 > NQ 10-10 & Saline. $ represents
NQ 10-20 being significantly higher than NQ 10-10 & Saline. * represent NQ 10-20 & NQ
10-10 being significantly higher than Saline. @ represent NQ#1 and Saline being significantly
higher than NQ 10-10. Significance determined through pairwise comparisons using
Benjamini-Hochberg corrections (p’s < 0.05).
Water Consumption
To assess whether water intake differed, a two-way ANOVA (Days of EtOH Exposure by
Neonatal Treatment Group) with repeated measures was fit to the data. Mauchly's test indicated
that the data violated the sphericity assumption, therefore sphericity corrections using
Greenhouse – Geisser were implemented. The repeated measures ANOVA demonstrated a
difference in water consumption, as it revealed a significant between-subjects effect of Neonatal
Treatment (F(2,27) = 4.459, p = 0.021, η2 = 0.248), a significant within-subjects effect of Days of
EtOH Exposure (F(9.671, 261.117) = 15.322, p < 0.001, η2 = 0.300), and an interaction effect of
Neonatal Treatment by Days of EtOH Exposure (F(19.342, 261.117) = 4.389, p < 0.001, η2 = 0.172).
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A post hoc Tukey’s test revealed that the NQ 10-20 and Saline groups differed significantly at p
= 0.029. Pairwise comparisons were fit to the data to assess group differences of water
consumption during individual days (Figure 5) indicating that the Saline group consumed
significantly more water than the NQ 10-20 and/or NQ 10-10 groups during Adulthood on PND
76, 78, 81, 84, 85, 87, and 89 (p’s < 0.01, Fig. 5) with a mean consumption difference of 8.626
grams. NQ 10-20 and Saline groups consumed significantly more water than the NQ 10-10
group on PND 86 (p < 0.001, Fig. 5) with a mean consumption difference of 12.056 grams.

10-20
10-10
PND
Figure 5. Treatment Group mean (+ SEM) water consumption during each day of EtOH exposure.
Panel A is the Adolescent Exposure Period and Panel B is the Adulthood Exposure Period. There
was a main effect of interaction between the NQ10-20 & Saline, denoted by * in the legend. $
represent Saline being significantly higher than NQ 10-20. * represent Saline being significantly
higher than NQ 10-20 & NQ 10-10. @ represent NQ#1 10-20 & Saline being significantly higher
than NQ 10-10. Significance determined through pairwise comparisons using Benjamini-Hochberg
corrections (p’s < 0.05).
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Table 2.
Descriptive statistics for EtOH consumption
Descriptive Statistics
Adolescent EtOH
Consumption
(with bottle leak)
NQ 10-20 NQ 10-10 Saline
10
10
10
N
2.329
2.519
1.608
Mean
1.242
1.024
0.3192
SD
1.273
1.275
1.14
Min
5.084
4.213
2.21
Max

Adolescent Adjusted
EtOH Consumption
(without bottle leak)
NQ 10-20
NQ 10-10 Saline
10
10
10
2.053
2.519
1.608
0.7833
1.024
0.3192
1.273
1.275
1.14
3.553
4.213
2.21

Adult EtOH
Consumption
NQ 10-20
10
3.096
0.9942
1.423
4.249

NQ 10-10 Saline
10
10
3.864
2.657
0.5579 0.7492
3.029
1.664
4.734
4.133

Note. An outlier was found in the adolescent quinpirole group; thus, it was reverted to the group
mean. Changes in the Quinpirole group mean before and after adjusting the outlier is indicated
above, in red.
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Table 3.
Repeated measures ANOVA for ETOH consumption
Between Subjects Effects
Sum of
Squares
Neonatal
126.0
Treatment
Residual
399.4

df

Mean
Square

2

63.000

27

14.79

F

p

η²

4.259 0.025

0.240

Note. Type III Sum of Squares

Within Subjects Effects
Sum of
Squares

df

Mean Square

F

p

η²

EtOH Exposure

309.8

8.926
(26.000)

34.710
(11.916)

7.717

6.565e -10
(7.163e -25)

0.191

EtOH Exposure *
Neonatal Treatment

225.9

17.852
(52.000)

12.653
(4.344)

2.813

1.900e -4
(1.186e -9)

0.139

Residual

1084.0

241.001
(702.000)

4.498
(1.544)

Note. Type III Sum of Squares. Mauchly’s test of sphericity indicates that the assumption of
sphericity is violated (p < 0.05). Greenhouse – Geisser corrections are noted in the table with values
prior to the corrections in parentheses.
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Table 4.
Descriptive Statistics for Food, Water, and Body Weight
Food
Consumption (g)
Ado
Adult
NQ 10-20
(n = 10)

NQ 10-10
(n = 10)

Saline
(n = 10)

Water
Consumption (g)
Ado
Adult

Body
Weight (g)
Ado
Adult

Mean
SD
Min
Max

13.335
1.170
11.5
15.457

15.223
1.010
13.827
16.700

16.149
4.224
10.664
23.750

18.926
4.195
14.400
28.233

111.236
9.431
96.329
124.764

235.712
12.022
213.014
251.357

Mean
SD
Min
Max

12.154
2.020
9.679
15.429

13.417
1.459
11.643
15.742

16.743
3.832
11.821
24.179

19.225
4.066
13.036
27.628

102.246
22.915
80.393
138.929

224.125
35.733
183.571
289.429

Mean
SD
Min
Max

12.218
0.819
10.633
13.400

13.517
0.937
12.536
15.750

19.061
3.165
14.464
25.679

24.674
3.381
18.451
30.393

92.979
4.216
87.571
99.464

193.896
9.429
180.607
205.893

Note. Ado = adolescent exposure period; Adult = adult exposure period.
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CHAPTER 5
DISCUSSION
The purpose of this experiment was to investigate EtOH consumption in the NQ model
of schizophrenia using the two-bottle 24 hr access paradigm with adolescent and adulthood
exposure periods. The data suggest an increased level of consumption in an animal model of
schizophrenia. Specifically, the NQ 10-10 group consumed significantly larger amounts of EtOH
than the Saline group. This significant increase in EtOH consumption occurred only in adulthood
beginning at PND 82 and lasted throughout the remainder of the study. The late onset of
increased consumption in the NQ 10-10 group could have been due to solution palatability
towards EtOH (Kiefer, 1995; Kiefer, Bice, & Badia-Elder, 1994). Previous studies (Kiefer &
Dopp, 1989) have demonstrated that rats may habituate to the taste of EtOH after a prolonged
exposure, which suggests that the taste towards EtOH has become less aversive.
Taste reactivity tests are a way to measure the hedonic value an organism attributes to a
gustatory stimulus (Kiefer & Dopp, 1989; for review see: Grill & Norgren, 1978). The
palatability of a substance can have a great impact on future consummatory behaviors (Grill &
Norgren, 1978). Specifically, concerning EtOH palatability in rats, EtOH concentrations
exceeding 15% have been shown to result in a diminished interest towards the EtOH, which is
represented as a lack of consumption (Kiefer et al., 1994). When conducting a two-bottle choice
task (one bottle containing water, one bottle containing EtOH) diminished interest in the EtOH
solution would result in an avoidance of the EtOH bottle and the subsequent consumption of
mostly water (Kiefer, 1995; Kiefer & Dopp, 1989).
In the current study, palatability could have affected the EtOH consumption amount of
the NQ 10-20 and Saline groups due to the increased EtOH concentration between adolescence
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(10%) and adulthood (20%). During adulthood, the two groups could have experienced aversive
reactions towards the 20% EtOH consequently causing the diminished intake levels seen in
Figure 2. Alternatively, the NQ 10-20 and Saline group could have increased their palatability
for the taste of EtOH but the increase in consumption did not occur due to the postingestional
factors associated with EtOH (Deutsch, Walton, & Thiel, 1978; Kiefer et al., 1994). However,
the prolonged exposure to the 10% EtOH concentration in the NQ 10-10 group seemed to
increase the palatability and decreases the aversion towards EtOH (Kiefer, 1995). The
habituation towards the solution took effect on PND 82, in which a significant increase of EtOH
consumption was observed for the remainder of the experiment.
During the adolescent exposure period, all three treatment groups consumed similar
amounts of EtOH. Even though one of the hypotheses of the present study suggested that NQ
rats would consume more EtOH during adolescence the results of there not being a difference
have been observed in previous research (Jeanblanc et al., 2014) as well. EtOH consumption in
humans also suggest that adults consume more than adolescents, overall, but adolescents
consume larger quantities of EtOH than adults on a single occasion (Spear, 2018). Since human
adolescents exhibit a tendency to consume large amounts of EtOH over a small period of time,
the assumption was that the adolescent rodents would show similar drinking behaviors.
During adulthood, beginning on PND 83, the NQ 10-10 group diverged from the other
treatment groups and chronically consumed more EtOH for the remainder of the study.
Unfortunately, there was not a Saline control group to compare NQ 10-10 group’s EtOH
consumption against. Since, there was not a control group for the NQ 10-10 group, the
interpretations of the data must be limited. A study using a three-bottle (10% EtOH, 10% diluted
white wine, & water) free-choice paradigm found that over a four-week period adult Sprague
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Dawley females consumed on average 7.17 g/kg/week of combined white wine and 10% EtOH
(Cacace, Plescia, Sardo, & Cannizzaro, 2012), which is significantly less than the amount of
EtOH consumed by the NQ 10-10 group in the current study.
Interestingly, the NQ 10-10 group exhibited a late onset of increased EtOH consumption,
commencing at PND 82. From a neurobiological perspective, the phenomena could be a
byproduct of neuroadaptation, by the brain trying to adapt to the effects of EtOH (Fadda &
Rossetti, 1998; Himmelsbach, 1941). Neuroadaptation can be triggered by chronic EtOH
administration and allows an organism to gain an increased tolerance to the substance. Increased
tolerance to EtOH would explain the delayed increase in EtOH consumption in the NQ 10-10
group (Fadda & Rossetti, 1998).
Unfortunately, the NQ 10-20 group did not significantly differ from the Saline group in
their ethanol consumption. The hypothesis that quinpirole would enhance EtOH consumption is
because EtOH has been shown to enhance dopaminergic transmission in the brain, specifically
from the VTA to the Acb (Di Chiara, 1997). EtOH enhances DA transmission directly, by
increasing DA firing rate from the VTA to the Acb (Deehan et al., 2013; Deehan et al., 2016;
Gilpin & Koob, 2008), and quinpirole super sensitizes D2-R in this pathway (Kostrezewa, 1993;
Peterson et al., 2017) creating an enhanced response to the increased flow of DA due to EtOH
consumption which would speculatively increase dependence to EtOH. Other factors namely,
change of adulthood EtOH exposure, rat strain, and sex differences, could have also contributed
to the insignificance in EtOH consumption between the NQ 10-20 group and the Saline group.
Change of Adulthood EtOH Exposure Period
The current study attempted to replicate a prior study (Jeanblanc et al., 2014) that
increased the EtOH percentage from 10% to 20% from the adolescent exposure period to
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adulthood. However, during the adulthood exposure period, the current study used an
unrestricted free-choice paradigm while Jeanblanc et al. (2014) conducted an intermittent access
two-bottle choice paradigm. The 20% intermittent access paradigm gives animals access to
EtOH every other day for 24 hours (Jeanblanc, 2014; Simms et al., 2008, Wise, 1973). This
method creates long-lasting high-EtOH preferencing by establishing an alcohol deprivation
effect (ADE). The ADE is a transient increase in voluntary consumption compared to baseline
due to the reinstatement of EtOH. The temporary increase in consumption allows rats to reach
pharmacologically significant blood EtOH concentrations (BECs) (Simms et al., 2008; Sinclair,
Hyytiä, & Nurmi, 1992). Thus, differing paradigms could be why different levels of
consumption were seen between the two studies.
Alternatively, the intake differences between groups could have been attributed to a floor
effect in EtOH consumption. During adulthood, NQ 10-20 and Saline rats consumed similar
amounts of EtOH, but the NQ 10-10 rats consumed significantly more EtOH than both groups.
The difference in EtOH concentration could contribute to why the NQ 10-10 rats consumed
significantly greater quantities of EtOH than the NQ 10-20 and Saline groups. Similarly, studies
have shown that rats prefer EtOH concentrations ranging from 5 to 15% (Myers & Eriksson,
1968). Although, a study assessing EtOH dose-response in Long-Evans rats, found that peak
responding occurred during 10% and 20% EtOH concentrations indicating that these doses
should exhibit similar reinforcing properties (Carnicella, Yowell, & Ron, 2011). Unless the
reinforcing properties of EtOH are dependent on the strain of rat.
Strain of Rat and EtOH Intake
In the current study, the non-significance of EtOH consumption between the NQ 10-20
and Saline groups could be attributed to a floor effect due to the rat strain used in the present
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study (Carnicella, Ron, & Barak, 2014). Sprague Dawley rats were utilized because all previous
NQ research used this rat strain (e.g. Brown et al., 2012; 2018a & b). EtOH intake can vary
tremendously depending on the strain of rat and even the supplier where that the rat was
purchased (e.g. Hosová & Spear, 2018; Palm, Roman, & Nylander, 2011; Simms et al., 2008; for
review see Carnicella et al., 2014). The most common outbred rat strain used for EtOH research
is the Wistar rat and because of their superior EtOH intake capabilities, this strain has also been
selectively bred to create lines of alcohol-preferring rats (e.g. Conte et al., 2019; Jadhav,
Magistretti, Halfon, Augsburger & Boutrel, 2017; Momeni, Segerström & Roman, 2015; Palm et
al., 2011; Priddy et al., 2017). However, some studies have used Long-Evans rats (e.g. Barak,
Ahmadiantehrani, Kharazia, & Ron, 2011, Doherty, & Gonzales, 2015; Li, Bian, Dave, & Ye,
2011; Simms et al., 2008) or Sprague Dawley rats (e.g. Bito-Onon, Simms, Chatterjee, Holgate,
& Bartlett, 2011; Hosová & Spear, 2019; Li et al., 2019; Martinetti et al., 2006) to assess EtOH
consumption. Even though the Wistar strain is the most commonly used rat strain for EtOH
studies, researchers have differing opinions on whether the Wistar strain is the best rat to use for
assessing EtOH consumption (Carnicella et al., 2014). With one study indicating that Sprague
Dawley rats voluntarily consumed the same amount of EtOH as Wistar rats and significantly
more EtOH than Long Evans Rats, using a sucrose fading paradigm (Gauvin, Moore, &
Holloway,1993). Contrarily, a systematic review (Carnicella et al., 2014) on the EtOH
consumption paradigm, intermittent access to EtOH in 2-bottle choice, concluded that LongEvans rats reached higher blood EtOH levels than other outbred rat strains. Other factors could
result in outbred rat strains to consume different amounts of EtOH. The type of paradigm used to
study EtOH consumption can greatly affect the amount consumed. For example, intermittent
access to 20% EtOH in 2-bottle choice will result in higher levels of consumption than a
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continuous access paradigm (Fu et al., 2015; Simms et al., 2008). Another factor that affects
consummatory behaviors is if palatability enhancers, such as saccharin or sucrose, are added to
the EtOH since it is known that rodents prefer sweet solutions (Boughter & Bachmanov, 2007;
Crabbe, Phillips, & Belknap, 2010).
Sex Differences and Quinpirole
A potential issue in the current study could be that only female rats were used. Since
sexual dimorphic behaviors are suggested in previous drug research utilizing the NQ model
(Brown et al., 2011; Cope et al., 2010; Kostrzewa et al., 2016; Thacker et al., 2006), it will be
important to further investigate whether sex differences are shown toward EtOH consumption
behavior in the NQ model. Acute injections of quinpirole during adulthood revealed that rats
injected with quinpirole yawn significantly more than those injected with saline, but male rats
yawn significantly more than female rats injected with quinpirole (Cope et al., 2010; Kostrzewa
et al., 2016; Thacker et al., 2006). This is important because yawning is a dopamine D2 receptormediated event (Kostrzewa, Brus, Rykaczewska, & Plech, 1993; Kostrzewa et al., 2016). There
are sex differences that reside in the development of the dopamine system, specifically in the
Acb and striatum (Str). Male rats have been shown to have an increased level of D1 - R from
adolescence into adulthood, while D2 - R levels in the Str seem to vary throughout adolescence
until approximately P60 when D2 - R levels stabilize and are similar to female expression
(Andersen & Teicher, 2000; Kostrzewa et al., 2016). Studies have assessed whether the
differences in DA levels are great enough to cause any sexual dimorphic behaviors in NQ rats,
with results suggesting female rats exhibit a reduced conditioned effect but an enhanced
behavioral activation to nicotine compared to male rats (Sheppard, Lehmann, Cope, & Brown,
2009). Additionally, research demonstrated that female NQ rats acutely treated with
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methylphenidate manifest significantly higher levels of locomotor activity, increased response,
and sensitization as opposed to male NQ rats (Cope et al., 2010). Interestingly, past work has
also revealed that adult female rats have been shown to consume more EtOH than adult male rats
(Alemedia et al., 1998; Priddy et al., 2017; Vetter-O’Hagen, Varlinskaya, & Spear, 2009).
Further investigations are required to assess the gender variations in NQ EtOH consummatory
behaviors.
Body Weight, Food, and Water
Bodyweight, food consumption, and water intake were recorded daily and analyzed to
view any variations between groups and the relationship between these variables and EtOH
consumption. NQ 10-20 rats weighed significantly more than Saline rats. Additionally, both
groups treated with quinpirole weighed significantly more than the Saline group throughout
adulthood. This finding correlates with the clinical population of schizophrenia that suggests that
the elevated risk of weight gain is perhaps due to dysfunction in anticipatory reward processing
in the striatum (Grimm, Kaiser, Plichta, & Tobler, 2017). The NQ 10-20 Treatment group was
also found to have consumed significantly more food than the NQ 10-10 and Saline Treatment
Groups. Studies have examined the relationship between food intake and EtOH consumption
finding that rats will decrease food consumption in direct proportion to EtOH intake (LarueAchagiotis, Paussard, & Louis-Sylvestre, 1990; Richardson, Rumsey, & Read, 1990). NQ 10-10
rats were consuming increased quantities of EtOH compared to the NQ 10-20 group or Saline
group, thus possibly reducing their food intake. Also, the differences in food consumption
between groups could have been a byproduct of changing the manner of how the food was
administered to the rats. For NQ 10-20 rats, the food was placed on top of the rats’ cages but for
the NQ 10-10 and Saline rats, the food pellets were placed in a hanging food hopper inside the
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rats’ cages. Intriguingly, Saline rats significantly consumed more water than the NQ 10-20 rats
but not the NQ 10-10 rats. Perhaps the 20% EtOH was less appealing to the Saline rats than the
NQ 10-20 rats. The current study’s hypotheses were partially supported in that the NQ 10-10
group did significantly consume more EtOH than the Saline group; but only during adulthood
and the EtOH concentrations were different, NQ 10-10 rats received 10% EtOH and the Saline
rats received 20% EtOH.
Conclusion
Overall, the data partially support the proposed hypotheses and provides further evidence
that EtOH consumption during adolescence significantly increases the amount of EtOH
consumed during adulthood. The data from the NQ 10-10 group seems promising in providing
partial evidence that NQ rats are a valid model for assessing EtOH consumption. Schizophrenia
is a detrimental psychiatric disorder that has a high disease burden due to premature mortality
(Hjorthøj et al., 2017). Several factors contribute to the elevated risk of mortality, namely the
increased frequency of drug abuse (APA, 2014; Green et al., 2007). Specifically, AUD effects
upwards to 65% of the schizophrenic population magnifying negative health outcomes (Volkow,
2009). Investigations have revealed that the elevated risk of AUD comorbid schizophrenia is due
to similar neuronal pathways being affected in both disorders (Nestler et al., 2015). This is the
first time the NQ model has been implemented to assess EtOH consumption using the two-bottle
choice task with two-exposure periods. Future studies will be needed to provide an enhanced
knowledge of AUD comorbid schizophrenia by using the NQ model of schizophrenia.
Future Directions
Future studies will aim to replicate the current study to increase the power and effect size
in hopes that this will delineate EtOH consumption between the NQ rats and Saline rats, as well
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as using male Sprague Dawley rats to examine the potential effect of sex differences on NQ
drinking behavior. Furthermore, an additional saline neonatal treatment group in which the
adulthood EtOH concentration is reduced from 20% to 10% needs to be implemented to extend
the interpretation of the adulthood drinking data for the NQ 10-10 animals. Results from the NQ
10-10 rats consuming an EtOH concentration of 10% seem very promising (shown in Figure 1)
but the evaluation of a control group must occur prior to any further inferences. A study
examining the effect of EtOH consumption only during adulthood in the NQ model would
provide valuable insight concerning whether the adolescent exposure period is a key factor for
increased EtOH consumption later in life. Rodent model research results have shown mixed
findings on the significance of EtOH consumption during adolescence. Some studies indicate
that EtOH consumption during adolescence increases drinking behavior in adulthood (Amodeo,
Kneiber, Wills, & Ehlers, 2017; Gilpin, Karanikas, & Richardson, 2012), while others have not
found significant differences in rats that were exposed to EtOH in adolescence versus those that
were not (Slawecki & Betancourt, 2002; Vetter, Doremus-Fitzwater, & Spear, 2007).
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